BRAF: which options do we have for these patients in second line?

Previous Page

Next Page

Page Background

BRAF

INHIBITION IN SOLID TUMORS

Joseph EW,

et al.

PNAS 2010; 107(33):14903-14908.

Non-specific

Sorafenib

Regorafenib

BRAFV600E specific

Vemurafenib

Dabrafenib

Encorafenib (LGX818)

RAF265/CHIR265

BMS-908662/XL281

(GSK2118436)

2

nd

generation

PLX8394

KRAS

BRAFi

PanRAFi

MEKi

MAPK

The “Paradox”

Slide coutrtesy of Jordi Rodon